Suppr超能文献

青光眼治疗的当前医学疗法及未来趋势

Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment.

作者信息

Cvenkel Barbara, Kolko Miriam

机构信息

Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.

出版信息

J Ophthalmol. 2020 Jul 21;2020:6138132. doi: 10.1155/2020/6138132. eCollection 2020.

Abstract

Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons. Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma. However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma. Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention. Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved. The present update provides an overview of currently available IOP-lowering medications. Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed. Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.

摘要

青光眼是一种神经退行性疾病,其特征是视网膜神经节细胞及其轴突逐渐丧失。降低眼压(IOP)是目前唯一经证实的青光眼治疗策略。然而,一些患者尽管眼压得到控制,但仍出现视野和生活质量的逐渐丧失,这表明青光眼还涉及其他因素。因此,能够预防或降低进展速度且不依赖于降低眼压的方法受到了广泛关注。在青光眼动物模型中已报道有有效的神经保护作用,但迄今为止,尚无神经保护剂获得临床批准。本综述概述了目前可用的降低眼压药物。此外,还讨论了降低眼压和神经保护治疗的潜在新靶点。最后,阐述了青光眼治疗的未来趋势,包括持续给药系统和个性化医学的进展。

相似文献

1
Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment.
J Ophthalmol. 2020 Jul 21;2020:6138132. doi: 10.1155/2020/6138132. eCollection 2020.
2
Present and New Treatment Strategies in the Management of Glaucoma.
Open Ophthalmol J. 2015 May 15;9:89-100. doi: 10.2174/1874364101509010089. eCollection 2015.
3
[Aiming for zero blindness].
Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194.
4
Neuroprotective agents in the management of glaucoma.
Eye (Lond). 2018 May;32(5):938-945. doi: 10.1038/s41433-018-0050-2. Epub 2018 Feb 23.
5
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.
Prog Retin Eye Res. 2017 Jan;56:107-147. doi: 10.1016/j.preteyeres.2016.10.001. Epub 2016 Oct 20.
7
Neuroprotection in glaucoma.
Indian J Ophthalmol. 2011 Jan;59 Suppl(Suppl1):S102-13. doi: 10.4103/0301-4738.73700.
8
The use of cyclodialysis to limit exposure to elevated intraocular pressure in rat glaucoma models.
Exp Eye Res. 2006 Jul;83(1):51-60. doi: 10.1016/j.exer.2005.10.032. Epub 2006 Mar 10.
9
Neuroprotection in glaucoma: recent advances and clinical translation.
Clin Exp Ophthalmol. 2019 Jan;47(1):88-105. doi: 10.1111/ceo.13336. Epub 2018 Jul 1.
10
Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma.
Life Sci. 2020 Feb 15;243:117303. doi: 10.1016/j.lfs.2020.117303. Epub 2020 Jan 14.

引用本文的文献

1
Research on neurotrophic factor for glaucoma: a worldwide bibliometric analysis.
Int J Ophthalmol. 2025 Sep 18;18(9):1747-1758. doi: 10.18240/ijo.2025.09.17. eCollection 2025.
4
The pivotal role of inflammatory factors in glaucoma: a systematic review.
Front Immunol. 2025 May 23;16:1577200. doi: 10.3389/fimmu.2025.1577200. eCollection 2025.
6
Unveiling the levels and significance of different serpin family proteins in aqueous humor dynamics.
BMC Ophthalmol. 2025 May 19;25(1):297. doi: 10.1186/s12886-025-04119-3.
7
Segmental Uveoscleral Outflow and its Relationship With Trabecular Outflow in Monkey Eyes.
Invest Ophthalmol Vis Sci. 2025 Apr 1;66(4):78. doi: 10.1167/iovs.66.4.78.
9
Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.
Front Med (Lausanne). 2025 Mar 26;12:1527319. doi: 10.3389/fmed.2025.1527319. eCollection 2025.
10
Damage and repair in retinal degenerative diseases: Molecular basis through clinical translation.
Neural Regen Res. 2026 Apr 1;21(4):1383-1395. doi: 10.4103/NRR.NRR-D-24-01016. Epub 2025 Feb 24.

本文引用的文献

1
Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
Ophthalmol Glaucoma. 2019 Sep-Oct;2(5):280-289. doi: 10.1016/j.ogla.2019.03.007. Epub 2019 Mar 28.
2
The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study.
Ophthalmology. 2020 Apr;127(4):477-483. doi: 10.1016/j.ophtha.2019.10.022. Epub 2020 Jan 10.
3
Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.
Adv Ther. 2020 Jan;37(1):155-199. doi: 10.1007/s12325-019-01163-6. Epub 2019 Dec 10.
5
Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.
Molecules. 2019 Oct 22;24(20):3805. doi: 10.3390/molecules24203805.
7
A review of systemic medications that may modulate the risk of glaucoma.
Eye (Lond). 2020 Jan;34(1):12-28. doi: 10.1038/s41433-019-0603-z. Epub 2019 Oct 8.
8
Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits.
Transl Vis Sci Technol. 2019 Sep 19;8(5):15. doi: 10.1167/tvst.8.5.15. eCollection 2019 Sep.
9
Melatonin and the control of intraocular pressure.
Prog Retin Eye Res. 2020 Mar;75:100798. doi: 10.1016/j.preteyeres.2019.100798. Epub 2019 Sep 25.
10
Ophthalmic Research Lecture 2018: DARC as a Potential Surrogate Marker.
Ophthalmic Res. 2020;63(1):1-7. doi: 10.1159/000500527. Epub 2019 Aug 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验